Suresh Chandrasekaran, MD
Interventional Cardiology · Midwest City, OKNPI 1649376427
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $272,883 of the $301,780 with a category attached, or 90.4%. 32 manufacturers reported payments, led by Novo Nordisk at 40.5% of the total. Reporting peaked in 2022 at $123,863 and has fallen 81.3% since, to $23,156 in 2024. Among interventional cardiology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 764 payments — averaging $395.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$122K
- AstraZeneca$61K
- Boehringer Ingelheim$36K
- Johnson & Johnson$28K
- Esperion Therapeutics, Inc.$18K
- Lilly USA, LLC$15K
- plus $21K from 26 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$272,88390%
- Travel & lodging$12,5844%
- Food & beverage$15,9015%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 80 | $122,078 |
| AstraZeneca | 134 | $60,538 |
| Boehringer Ingelheim | 88 | $36,285 |
| Johnson & Johnson | 111 | $28,371 |
| Esperion Therapeutics, Inc. | 27 | $18,457 |
| Lilly USA, LLC | 39 | $14,558 |
| E.r. Squibb & Sons, L.L.C. | 60 | $12,239 |
| Merck | 48 | $3,543 |
| Medtronic(2 entities) | 8 | $1,156 |
| Amgen | 30 | $1,034 |
| Novartis | 44 | $591 |
| Globus Medical | 3 | $563 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $507 |
| Atricure, Inc. | 4 | $315 |
| Shockwave Medical, Inc | 2 | $214 |
| Sanofi-aventis U.S. LLC | 6 | $202 |
| Vifor Pharma, Inc. | 10 | $197 |
| Abbott | 7 | $169 |
| Amarin Pharma, Inc. | 10 | $164 |
| Abiomed | 1 | $131 |
| Pfizer | 8 | $125 |
| Kestra Medical Technology Services, Inc. | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 4 | $56 |
| Lexicon Pharmaceuticals, Inc. | 2 | $51 |
| Lundbeck LLC | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $14 |
| Gilead | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$90,716
- FARXIGA$58,843
- JARDIANCE$49,324
- XARELTO$26,641
- NEXLIZET$18,145
- NEXLETOL$18,145
- RYBELSUS$12,105
- ELIQUIS$11,587
- VERQUVO$5,559
- TurboHawk$883
- CREO MCS, Fenestrated, Sideloading$536
- Repatha$330
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$233
- Impella$131
- Claria MRI$119
- Vascular Lithotripsy$117
- TOUJEO$100
How this compares
$301,780 in reported general payments places this provider in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 652 | $698,704 |
| EliquisApixaban | 617 | $583,056 |
| FarxigaDapagliflozin Propanediol | 449 | $428,655 |
| EntrestoSacubitril/Valsartan | 328 | $368,061 |
| OzempicSemaglutide | 275 | $355,518 |
| XareltoRivaroxaban | 281 | $305,999 |
| TrulicityDulaglutide | 114 | $163,094 |
| MounjaroTirzepatide | 91 | $134,879 |
| BrilintaTicagrelor | 89 | $63,146 |
| Rosuvastatin Calcium | 2,401 | $56,590 |
| VerquvoVericiguat | 53 | $55,504 |
| VascepaIcosapent Ethyl | 68 | $36,305 |
| Ezetimibe | 855 | $32,989 |
| Repatha SureclickEvolocumab | 31 | $30,389 |
| ClopidogrelClopidogrel Bisulfate | 1,050 | $20,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $36,285 | $698,704652 claims |
| PfizerEliquis | $125 | $583,056617 claims |
| AstraZenecaFarxiga, Brilinta | $60,538 | $491,801538 claims |
| Novo NordiskOzempic, Rybelsus | $122,078 | $373,240287 claims |
| NovartisEntresto | $591 | $368,061328 claims |
| Johnson & JohnsonXarelto | $28,371 | $305,999281 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $14,558 | $297,973205 claims |
| MerckVerquvo | $3,543 | $55,50453 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $202 | $14,09517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Midwest City
- Jerome MathiasMidwest City$11K
- Mohammed AhmedMidwest City$9K
- Kamran MuhammadTulsa$1.4M
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Stanley ZimmermanTulsa$93K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.